placeholder image

Rakesh K. Singh Adjunct Associate Professor of Obstetrics and Gynecology

I have been trained in the art of design, synthesis and biological screening of small molecules, unnatural amino acids and peptides during my studies in chemistry. I expanded my training in small molecule drug discovery research during my long tenure with Ranbaxy Research laboratories in India. Currently I focus on the identification of novel anticancer agents and their mechanism of action. I also seek to understand the mechanistic basis of disease markers. My recent research efforts are expanding and directed partially at identifying new insulin secretagogues and understanding biological functions and targeting ovarian cancer stem cells.

Brown Affiliations

research overview

Ours is the basic science laboratory of the Womens Oncology program of Women and Infants Hospital. We discover and delineate mechanism of action of new anticancer agents. Biological functions of ovarian cancer markers and ovarian cancer stem cells are also studied. We have discovered various classes of anticancer agents including the first non-hypercalcemic vitamin-D derived MT19c and PT19c endowed with excellent safety and efficacy against ovarian cancer, endometrial cancer and neuroblastoma.

research statement

Our laboratory is focused on the discovery of new classes of anticancer agents and delineation of the mechanism of their antitumor actions. Further, we strive to understand the mechanistic basis of ovarian cancer markers and ovarian cancer stem cells. Our efforts have resulted in the discovery of the first non-hypercalcemic vitamin-D derived anticancer agents MT19c and PT19c. These agents including variety of other new structural classes of anticancer agents discovered by us have shown promising safety and antitumor efficacy profiles in animal models of epithelial ovarian cancer, endometrial cancer, neuroblastoma and medulloblastoma. In our laboratory, genome-wide mRNA analysis and copy number changes as tumors evolved over the time have revealed key drivers of ovarian cancer and at present, the efficacy of small molecules or phosphorothioates (PTOs) that inhibit the biological functions of these drivers is being studied. Our laboratory is also developing and evaluating new classes of insulin secretagogues for the treatment of type-II diabetes in humans.